Relevance of the ferret model of Helicobacter-induced gastritis to evaluation of antibacterial therapies

American Journal of Gastroenterology

Volumn 91, Issue 11, 1996, Pages 2347-2354

  Alder, J D ^a   Ewing, P J ^a   Mitten, M J ^a   Oleksijew, A ^a   Tanaka, S K ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL THERAPY; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; FERRET; GASTRITIS; HELICOBACTER PYLORI; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STOMACH BIOPSY;

AMOXICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CLARITHROMYCIN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; FERRETS; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER; HELICOBACTER INFECTIONS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; OMEPRAZOLE; PENICILLINS; TIME FACTORS;

EID: 0029832827     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Lambert J, Borromeo M, Pinkard K, et al. Colonization of gnotobiotic piglets with Campylobacter pylori: An animal model? J Infect Dis 1987;155:1344.
2. Krakowka S, Morgan D, Kraft W, et al. Establishment of gastric Campylobacter pylori infection in the neonatal gnotobiotic piglet. Infect Immun 1987;55:2789-96.
3. Newell DG. Campylobacter pylori infections in non-human primates. In: Rathbone B, Heatley V, eds. Campylobacter pylori and gastroduodenal disease. Oxford, UK: Blackwell, 1989:265-73.
4. Baskerville A, Newell DB. Naturally occurring chronic gastritis and C. pylori infection in the rhesus monkey: A potential model for gastritis in man. Gut 1988;29:465-72.
5. Radin JM, Eaton KA, Krakowa DR, et al. Helicobacter pylori infection in gnotobiotic dogs. Infect Immun 1990;58:2606-12.
6. Lee A, Fox JG, Otto G, et al. A small animal model of Helicobacter pylori active chronic gastritis: Helicobacter felis in germfree mice. Gastroenterology 1990;99:1315-23.
7. Fox JG, Correa P, Taylor NS, et al. Helicobacter mustelae-associated gastritis in ferrets: An animal model of Helicobacter pylori gastritis in humans. Gastroenterology 1990;99:352-61.
8. 14C-urea breath test in ferrets colonized with Helicobacter mustelae: Effects of treatment with bismuth, antibiotics, and urease inhibitors. Gut 1993; 34:181-6.
9. NIH Consensus Development Conference. Helicobacter pylori in peptic ulcer disease. National Institutes of Health, Bethesda MD JAMA 1994;272:65-9.
10. Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation. BMJ 1991;302:1302-5.
11. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and risk of gastric carcinoma. N Eng J Med 1991;335:1127-31.
12. Nomura A, Stemmermann GN, Chyou P, et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. New Engl J Med 1991;325:1132-6.
13. Tompkins LS, Falkow S. The new path to preventing ulcers. Science 1995;267:1621-2.
14. Covacci AS, Censini M, Bugnoli R, et al. Molecular characterization of the 128 kDa immunodominant agent of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci USA 1993;90:5791-5.
15. Crabtree JE, Taylor JD, Wyatt JI, et al. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration and gastric pathology. Lancet 1991;338:332-3.
16. Sipponen PM, Sturata M, Goodwin CS. Histology and ultrastructure of Helicobacter pylori infections: Gastritis, duodenitis and peptic ulcer and their relevance as precancerous conditions. In: Goodwin CS, Worsley BW, eds. Helicobacter pylori: Biology and clinical practice. Boca Raton, FL: CRC Press, 1994:37-62.
17. Telford JL, Ghiara P, Dell'Orco M. Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. J Exp Med 1994;179:1653.
18. Tummuru MKR, Cover TL, Blaser MJ. Mutation of the cytotoxin-associated cagA gene does not affect the vacuolating cytotoxin activity of Helicobacter pylori. Infect Immun 1994;62:2609-13.
19. Iseuberg JT. Acid-peptic disorders. In: Yamada T, ed. Textbook of gastroenterology, vol 1. Philadelphia, PA: JB Lippincott, 1991:1241-1339.
20. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long term recurrence of gastric duodenal ulcer: A randomized controlled study. Ann Intern Med 1992; 116:705-8.
21. Rauws EAJ, Tytgat GNJ. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990;335:1233-5.
22. Peterson WL, Graham DY, Marshall B, et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: A randomized double blind trial. Am J Gastroenterol 1993;88:1860-4.
23. Marshall B. Newer approach to H. pylori infection. Infect Med 1994; 11(suppl):27-31.
24. Graham DY, Opekumm A, Klein PD. Clarithromycin for the eradication of H. pylori. J Clin Gastroenterol 1993;16:292-4.
25. Logan RPH, Bardhan KD, Celestin LR, et al. Healing of DU and eradication of H. pylori by clarithromycin and omeprazole. Gastroenterology 1994;106:A126 (abstract).
26. Cederbrant G, Kahlmeter G, Schalen C, et al. Additive effect of clarithromycin combined with 14-OH-clarithromycin, erythromycin, amoxiycillin, metronidazole or omeprazole against Helicobacter pylori. J Antimicrob Chemother 1994;34:1025-9.
27. Gustavson LE, Kaiser JF, Mukherjee DX, et al. Evaluation of the pharmacokinetic drug interactions between clarithromycin and omeprazole. Antimicrob Agents Chemother 1995;39:2078-83.
28. Satoh K, Kimura K, Taniguchi Y, et al. Evaluation of endoscopic topical therapy regimens of amoxicillin, bismuth subnitrate, and metronidazole in treating Helicobacter pylori. Gastroenterology 1995; 108(suppl 4):A210 (abstract).
29. Adamek RJ, Wegener M, Opferkuch W, et al. Successful Helicobacter pylori eradication: A systemic effect of antibiotics? Am J Gastroenterol 1993;88:792-3.
30. Hardy DJ, Swanson RN, Hensey DM, et al. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones. Antimicrob Agents Chemother 1987;31:1768-1774.
31. Whitehead R, Truelove SC, Gear MWL. The histological diagnosis of chronic gastritis in fibreoptic gastroscope biopsy specimens. J Clin Pathol 1972;25:1-11.
32. Whitehead R. Mucosal biopsy of the gastrointestional tract. London, UK: WB Saunders, 1990.
33. Fernandez PB, Ramer N, Rode RA, et al. Bioassay for A-56268 (TE-031) and identification of its major metabolite, 14-hydroxy-6-O-methyl erythromycin. Eur J Clin Microbiol Infect Dis 1988;7:73-6.
34. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: Sixth informational supplement. Wayne, PA: 1995.
35. Glupcznski Y, Burette A. Drug therapy for Helicobacter pylori infections: Problems and pitfalls. Am J Gastroenterol 1990;85:1545-51.